The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback